About this event

  • Date and time Thu 2 Dec 2021 from 6:00pm to 8:00pm
  • Location Online
  • Organised by Respiratory Medicine

This is a free event

Join this webinar that highlights the latest advances in the diagnosis and management of Interstitial Lung Disease (ILD).

Talks will be given by world experts in ILD and will be tailored to an audience of general respiratory physicians. The webinar will finish with an interactive panel discussion that will cover future directions in ILD.

Aims for this event include:

  • To highlight the importance of genetics in the early diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
  • To demonstrate the potential for biomarkers to stratify IPF to different targeted therapies
  • To highlight the latest advances in the management of connective tissue disease-related ILD

CPD learning accredited.

This webinar is available for on-demand viewing. The webinar recording will be available for registered delegates up to 30 days after the live webinar broadcast via Zoom. The link will be sent 24 hours after the webinar takes place. 

Join in the conversation online by using #RSMLive 
Follow us on Twitter: @RoySocMed

Key speakers

Louise Wain

Professor Louise Wain

Genetic Epidemiologist at the University of Leicester, Chair of Respiratory Research at the British Lung Foundation

Speaker's biography

Louise Wain was appointed in 2017 as a GSK/British Lung Foundation Chair of Respiratory Research and is a member of the Genetic Epidemiology group at the University of Leicester. She has research interests in the genetic architecture of respiratory health and disease, focusing on pulmonary fibrosis and chronic obstructive pulmonary disease. Her areas of expertise include the analysis of single nucleotide polymorphisms and copy number variation (CNV) using array data and re-sequencing approaches. Louise has played a key role in large consortium projects including SpiroMeta (lung function), the International Consortium for Blood Pressure (ICBP) GWAS and has led the largest GWAS of IPF susceptibility to date. Louise was a co-lead of the UK BiLEVE study - the first genetic study in UK Biobank - and is an active researcher working on pulmonary fibrosis in the Genomics England 100,000 Genomes Project. Louise is an Associate Editor for the European Respiratory Journal and, in addition to teaching at undergraduate and Masters level, leads doctoral training programme activities at the University of Leicester. She is currently one of the lead investigators of the new Post-Hospitalisation COVID-19 (PHOSP-COVID) Study and co-investigator of the largest UK study of post-COVID ILD.

Dr Puja Mehta

Dr Puja Mehta

Clinical Research Training Fellow at University College London 

Speaker's biography

Puja Mehta is a senior specialist registrar in Rheumatology in the London Deanery and is undertaking basic research in post-COVID interstitial lung disease (ILD) at UCL Respiratory.

Her research interests include rheumatic-associated ILD and experimental therapeutics.
During a pharmaceutical industry fellowship, Puja designed an interventional clinical trial of a monoclonal antibody in rheumatoid arthritis and an observational study to delineate the natural history of rheumatoid-arthritis-associated ILD (RA-ILD) to contextualise potential pulmonary safety signals.

Puja regularly teaches medical students and MSc students at UCL and Imperial College London.

Professor Gisli Jenkins

Professor Gisli Jenkins

Chair of Thoracic Medicine at the National Heart & Lung Institute

Speaker's biography

His clinical and research focus is on interstitial lung disease and pulmonary fibrosis. There are three major themes of his research. 1) Understanding the functional consequences of genetic risk factors for the development and progression of pulmonary fibrosis. 2) Using pre-clinical models of disease to try and therapeutically manipulate molecular pathways to prevent the development or progression of fibrosis. 3) Undertaking a detailed assessment of patient cohorts with fibrotic disease using the PROFILE and INJUSTIS (The its not just idiopathic pulmonary fibrosis study) or potentially fibrotic disease UKILD Post COVID-19 (the UK interstitial lung disease post-COVID-19 study) to understand the risk factors and biomarkers that may predict the development of repair or fibrosis.

He completed his medical training at the University of Southampton before undertaking postgraduate training in respiratory medicine in London. During this time, he undertook basic scientific training funded by an ARC Fellowship (Applied research collaboration) and obtained a PhD in Biochemistry from University College London before doing post-doctoral studies at the University of California at San Francisco funded by an ARC Clinician Scientist Fellowship.

In 2005 he returned to the UK as a clinical senior lecturer at the University of Nottingham. In 2021 he moved to Imperial College London to lead the Margaret Turner Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute.

He is currently the familial pulmonary fibrosis lead for the Genomics England Clinical Interpretation Partnership in Respiratory Medicine and is the Post Hospitalisation (PHOSP)-COVID-19 study fibrosis working group leader and leads the UK Interstitial Lung Disease consortium. He has been the joint editor-in-chief of the official journal of the British Thoracic Society since 2015. He was chair of the British Thoracic Society Science and Research Committee from 2016-2018.

He is a founding trustee of the patient charity Action for Pulmonary Fibrosis and is the clinical lead for the James Lind Alliance Priority Setting Partnership.


View programme

Welcome and introduciton

Dr Sachin Ananth, Foundation Year Two Doctor, West Hertfordshire NHS Trust

Genetics in the early diagnosis of Idiopathic Pulmonary Fibrosis (IPF)

Professor Louise Wain, Chair of Respiratory Research, British Lung Foundation and Genetic Epidemiologist, University of Leicester

Personalised medicine in Interstitial Lung Disease (ILD)

Professor Gisli Jenkins, Chair of Thoracic Medicine, National Heart and Lung Institute

Management of rheumatoid-arthritis associated Interstitial Lung Disease (ILD)

Dr Puja Mehta, Clinical Research Training Fellow, University College London

Panel discussion
Close of meeting



Disclaimer: All views expressed in this webinar are of the speakers themselves and not of the RSM.

Registration for this webinar will close 2 hours prior to the start time. You will receive the webinar link 2 hours before the meeting. Late registrations will not be accepted. 

Special rates for difficult times
The RSM wishes to offer healthcare professionals continued learning opportunities during the coronavirus pandemic. The RSM’s ​weekly COVID-19 Series ​webinars remain free of charge, while there will be small charges to register for other online education. These fees will enable the RSM to continue its programme of activities and will apply during the course of the pandemic.

Man searching computer

Join the RSM and get free access to digital learning resources

The RSM has an extensive digital learning and online e-resources platform. As a member you'll enjoy free access to a wealth of online  resources, including 5,000 subscription and open access e-journals, 2,000 e-books and 5 key medical databases, to support your clinical decision-making and research.

Become a member